Homocysteine: A novel risk factor in vascular disease

Coronary Health Care

Volumn 5, Issue 2, 2001, Pages 89-99

  Auer, J ^a   Berent, R ^a   Eber, B ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BETAINE; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN; METHIONINE; MULTIVITAMIN; PLACEBO; PYRIDOXINE; RIBOFLAVIN; SIMVASTATIN;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM INJURY; EVIDENCE BASED MEDICINE; GENETIC DISORDER; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; META ANALYSIS; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SCREENING; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBUS; VASCULAR DISEASE; VEIN THROMBOSIS; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 0034748594     PISSN: 13623265     EISSN: None     Source Type: Journal    
DOI: 10.1054/chec.2001.0121     Document Type: Article

References (79)

1. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction
2. Homocystein and fibrinolysis in acute occlusive coronary events
3. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia
4. Homocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
5. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intake
6. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease
7. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine (beta)-synthase deficiency
8. Folic acid - An innocuous means to reduce plasma homocysteine
9. 6, pyridoxal phosphate, and folate
10. Homocysteine and thrombotic disease
11. Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers
12. Disordered methionine/homocysteine metabolism in premature vascular disease: Its occurrence, cofactor therapy, and enzymology
13. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: Effect of treatment with folic acid
14. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study
15. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum
16. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
17. Homocysteine and risk of premature coronary disease: Evidence for a common gene mutation
18. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project
19. High homocysteine, low folate, and low vitamin B6 concentrations: Prevalent risk factors for vascular disease in heart transplant recipients
20. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects
21. Homocysteine and vascular disease
22. Homocystinemia: Vascular injury and arterial thrombosis
23. Oxidation of low density lipoprotein by thiols: Superoxide-dependent and -independent mechanisms
24. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells
25. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease
26. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol
27. The spectrum of diseases of small coronary arteries and their physiologic consequences
28. Hyperhomocysteinaemia as a risk factor for occlusive vascular disease
29. Homocysteinaemia due to folate deficiency
30. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
31. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinaemia
32. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase
33. Plasma homocysteine in the acute and convalescent phases of stroke
34. The oxidant stress of hyperhomocysteinaemia
35. Plasma homocysteine levels and graded risk for myocardial infarction: Findings in two populations at contrasting risk for coronary heart disease
36. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
37. Prevalence of hyperhomocysteinaemia in patients with peripheral arterial occlusive disease
38. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes
39. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischaemic cerebrovascular disease
40. Homocysteine and coronary atherosclerosis
41. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
42. Homocysteine metabolism in scurvy, growth and arteriosclerosis
43. Homocysteine and vascular disease
44. Disorders of transsulfuration
45. The natural history of homocystinuria due to cystathionine beta-synthase deficiency
46. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages
47. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells
48. Plasma homocysteine levels and mortality in patients with coronary artery disease
49. Total plasma homocysteine and cardiovascular risk profile
50. Remethylation defects: Guidelines for clinical diagnosis and treatment
51. Vitamins and progression of atherosclerosis in hyperhomocysteinaemia
52. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
53. Meta-analysis of hyperhomocysteinaemia as a risk factor for venous thromboembolic disease
54. Homocysteine and cardiovascular disease
55. Assessment of homocysteine status
56. Interrelation of hyperhomocysteinaemia, factor V Leiden, and risk of future venous thromboembolism
57. Homocysteine, B vitamins, and risk of cardiovascular disease
58. Hyperhomocysteinaemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease
59. Homocysteine, and atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells
60. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds
61. B vitamin supplementation lowers homocysteine levels in heart disease
62. Sensitivity of serum methylmalonic acid and total homocysteine determinants for diagnosing cobalamin and folate deficiencies
63. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
64. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry
65. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
66. S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds
67. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians
68. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine
69. Clinical implications of plasma homocysteine measurement in cardiovascular disease
70. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
71. Homocysteine species as components of plasma redox thiol status
72. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy
73. Total homocysteine in plasma or serum: Methods and clinical applications
74. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease
75. Vitamin B6 nutrition status and cigarette smoking
76. Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF-(kappa) B dependent transcriptional activation of NOS-2
77. Hyperhomocysteinaemia and atherothrombosis
78. Modeling of risk factors for ischemic stroke: The Willis lecture
79. The natural history of vascular disease in homocystinuria and the effects of treatment